Search
Cardiolipin Biosynthesis CL(i-14:0/i-21:0/i-21:0/i-21:0)
smpdb.ca/view/SMP0486713MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(i-14:0/i-21:0/i-22:0/i-22:0)
smpdb.ca/view/SMP0486778MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(i-14:0/i-21:0/i-24:0/i-24:0)
smpdb.ca/view/SMP0486815MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(i-15:0/i-21:0/i-21:0/i-21:0)
smpdb.ca/view/SMP0487036MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Cardiolipin Biosynthesis CL(i-15:0/i-22:0/i-22:0/i-24:0)
smpdb.ca/view/SMP0491912MetabolicCardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalIt was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and
Products: STELARA IV, Steqeyma IVSoybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. … It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.
Mixtures: No name provided, LIPOFUNDIN N EMULSION FOR INFUSION 20 %Products: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %NGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[A244750] Glucarpidase is an enzyme that can rapidly hydrolyze methotrexate into its nontoxic metabolites. … This can lead to delayed renal clearance of methotrexate and elevated drug plasma levels, increasing the risk of methotrexate toxicity.
Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1
go.drugbank.com/bio_entities/BE0008997TargetHumansS-adenosyl-L-methionine-dependent methyltransferase that mediates mRNA cap1 2'-O-ribose methylation to the 5'-cap structure of mRNAs.
Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1Synonyms: Cap methyltransferase 1